Lung Marker Market Report by Cancer Type (Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), Marker Type (EGFR, EML4-ALK, KRAS, BRAF, and Others), End User (Hospitals, Diagnostic Labs, and Others), and Region 2025-2033
폐 마커 세계 시장 규모는 2024년 4억 8,220만 달러에 달했습니다. 향후 IMARC Group은 시장이 2033년까지 11억 460만 달러에 달할 것으로 예상하며, 2025년부터 2033년까지 9.6%의 연평균 성장률(CAGR)을 기록할 것으로 예측했습니다.
일반적으로 EGFR, EML4-ALK, KRAS, BRAF를 포함한 4가지 주요 폐 표식자는 폐 중재 시술, 폐 수술, 진단 시 사용됩니다. 또한, 마커는 종양의 탐지, 진단, 예측, 모니터링에 사용되며, 이를 바탕으로 환자에게 치료법을 처방합니다. 폐 마커는 일부 영상 검사 및 생검과 함께 암을 식별하기 위한 추가 도구로만 사용됩니다. 이러한 이유로 폐 마커는 병원, 외래 수술 클리닉, 전문 클리닉 등 여러 의료 시설에서 흉강경 수술에 널리 사용되고 있습니다.
대기오염의 증가로 인한 흉수, 흉막 중피종, 흉막 플라크와 같은 호흡기질환의 유병률 증가가 폐 마커자 수요 증가의 배경이 되고 있습니다. 여기에 더해 간접흡연에 대한 높은 노출과 폐암의 가족력이 폐암 환자 수를 더욱 증가시켜 폐암 마커에 대한 수요를 증가시킬 것입니다. 또한, 노령 인구의 급증과 높은 흡연율로 이어지는 바쁜 소비자 라이프스타일은 일부 호흡기질환의 위험을 더욱 가속화하고 있습니다. 이와는 별도로, 폐암과 같은 생명을 위협하는 질병의 조기 진단 및 사전 치료를 위해 각국 정부의 의료비 지출이 증가함에 따라 전 세계적으로 폐 마커의 사용이 증가하고 있습니다. 또한, 폐암 진단 및 치료 분야의 여러 연구 개발 활동에 대한 투자가 증가함에 따라 폐 마커에 대한 수요를 더욱 자극하고 있습니다. 이 외에도 병원, 수술 센터, 클리닉에서 폐 마커의 사용량 증가와 치료 목적의 다양한 용도도 제품 수요를 자극하고 있습니다.
본 보고서에서 다루는 주요 질문
- 세계 폐 마커 시장은 지금까지 어떻게 성장해 왔을까?
- COVID-19는 세계 폐 마커 시장에 어떤 영향을 미치고 있는가?
- 주요 지역 시장이란?
- 암 유형별 시장 현황은?
- 마커 유형별 시장 분석은?
- 최종사용자별 시장 분석은 어떻게 되는가?
- 산업 가치사슬의 다양한 단계는 무엇인가?
- 업계의 주요 촉진요인과 과제는 무엇인가?
- 세계 폐 마커 시장의 구조와 주요 플레이어는?
- 업계 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 폐 마커 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 암 유형별
- 비소세포폐암(NSCLC)
- 소세포폐암(SCLC)
제7장 시장 내역 : 마커 유형별
- EGFR
- EML4-ALK
- KRAS
- BRAF
- 기타
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
- 북미
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 아시아태평양
- 라틴아메리카
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 칠레
- 페루
- 기타
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 구매자의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 참여업체의 위협
- 대체품의 위협
제13장 가격 지표
제14장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Abbott Laboratories
- Thermo Fisher Scientific Inc
- Agilent Technologies, Inc.
- Beckman Coulter, Inc.
- Fujirebio Europe N.V.
- Hologic, Inc.
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers
- BioSpace, Inc.
ksm
The global lung marker market size reached USD 482.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,104.6 Million by 2033, exhibiting a growth rate (CAGR) of 9.6% during 2025-2033.
Generally, four major types of lung markers, including EGFR, EML4-ALK, KRAS, and BRAF, are used during lung intervention procedures or lung surgeries and diagnosis. Furthermore, the markers are used to detect, diagnose, predict, and monitor the tumor, based on which the treatment is prescribed to the patient. Lung markers are only used as an additional tool to identify cancer along with several imaging tests and biopsy. Owing to this, lung markers are extensively used in thoracoscopic surgeries across hospitals, ambulatory surgical clinics, and specialty clinics, among several other healthcare facilities.
The rising demand for lung markers can be attributed to the high prevalence of respiratory disorders, such as pleural effusion, pleural mesothelioma, pleural plaque, etc., due to the increasing air pollution levels, across the globe. Besides this, the high exposure to passive smoking, along with a family history of lung cancer further drives the number of patients suffering from lung cancer, thereby augmenting the demand for lung markers. Additionally, the surging geriatric population, along with the hectic consumer lifestyles leading to a high smoking rate, further accelerate the risks of several respiratory disorders. Apart from this, the increasing healthcare expenditures by various governments for early diagnosis and pre-treatment of life-threatening diseases, such as lung cancer, are also propelling the rising utilization of lung markers at a global level. Furthermore, rising investments in several research and development activities in the field of lung cancer diagnostics and treatment is further catalyzing the demand for lung markers. In addition to this, the increasing usage of lung markers in hospitals, surgery centers, clinics, and their various applications in therapeutic purposes has also catalyzed the product demand.
Key Market Segmentation:
Breakup by Cancer Type:
- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
Breakup by Marker Type:
- EGFR
- EML4-ALK
- KRAS
- BRAF
- Others
Breakup by End User:
- Hospitals
- Diagnostic Labs
- Others
Breakup by Region:
- North America
- United States
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Chile
- Peru
- Others
- Middle East and Africa
- Turkey
- Iran
- Others
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Beckman Coulter, Inc., Fujirebio Europe N.V., Hologic, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers, and BioSpace, Inc.
Key Questions Answered in This Report:
- How has the global lung marker market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global lung marker market?
- What are the key regional markets?
- What is the breakup of the market based on the cancer type?
- What is the breakup of the market based on the marker type?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global lung marker market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Lung Marker Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact Of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Cancer Type
- 6.1 Non-Small Cell Lung Cancer (NSCLC)
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Small Cell Lung Cancer (SCLC)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Marker Type
- 7.1 EGFR
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 EML4-ALK
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 KRAS
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 BRAF
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Diagnostic Labs
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Europe
- 9.2.1 Germany
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 France
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 United Kingdom
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 Italy
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Spain
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Russia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Asia Pacific
- 9.3.1 China
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 Japan
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 India
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 South Korea
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Australia
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Indonesia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Argentina
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.4 Colombia
- 9.4.4.1 Market Trends
- 9.4.4.2 Market Forecast
- 9.4.5 Chile
- 9.4.5.1 Market Trends
- 9.4.5.2 Market Forecast
- 9.4.6 Peru
- 9.4.6.1 Market Trends
- 9.4.6.2 Market Forecast
- 9.4.7 Others
- 9.4.7.1 Market Trends
- 9.4.7.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Turkey
- 9.5.1.1 Market Trends
- 9.5.1.2 Market Forecast
- 9.5.2 Iran
- 9.5.2.1 Market Trends
- 9.5.2.2 Market Forecast
- 9.5.3 Others
- 9.5.3.1 Market Trends
- 9.5.3.2 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Indicators
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Thermo Fisher Scientific Inc
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Agilent Technologies, Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Beckman Coulter, Inc.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Fujirebio Europe N.V.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Hologic, Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.7 F. Hoffmann-La Roche Ltd
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Siemens Healthineers
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 BioSpace, Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
